Surrey Heartlands

Joint Formulary & PAD

Cinacalcet hydrochloride - Hypercalcaemia in parathyroid carcinoma

You are here : Home > Formulary Search > Cinacalcet hydrochloride - Hypercalcaemia in parathyroid carcinoma

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Cinacalcet hydrochloride
Indication :
Hypercalcaemia in parathyroid carcinoma
Group Name :
Keywords :
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Cinacalcet hydrochloride is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Hypercalcaemia in parathyroid carcinoma.

  • No records returned.

Committee Recommendations (1)

06 Oct 21 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

This drug/device has not yet been assessed for formulary status and is not currently on the APC work-plan for this indication

This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug / device.

The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.